Research & Development

Gilead, Carna Biosciences collaborate to develop novel immuno-oncology therapies

Gilead Sciences and Carna Biosciences announced that the companies have entered into a research and development collaboration to develop and commercialise small molecule compounds in immuno-oncology and to access Carna’s proprietary lipid kinase drug discovery platform.

Alnylam announces progress with RNAi Therapeutics platform

Alnylam Pharmaceuticals has announced new advances in its RNAi therapeutics platform, including preclinical results demonstrating oral delivery of GalNAc-conjugated small interfering RNAs (siRNAs) – the molecules that mediate RNAi – directed to a liver target.

Janssen announces collaboration with US universities to expand data science research in healthcare

Janssen Research & Development, LLC, part of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), today announced a collaboration with the University of California, Berkeley (UC Berkeley) and the University of California, San Francisco (UCSF), with the goal of inspiring data-driven approaches to improve health and develop the next generation of leaders in healthcare data sciences.

Gilead, Nurix collaborate to develop novel treatments for cancer and other diseases

Gilead Sciences has entered into a strategic collaboration with Nurix Therapeutics for the development of novel therapies for cancer and other diseases.

Mycovia, Jiangsu Hengrui to develop and commercialize antifungal therapy VT-1161

Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine announced an exclusive agreement to develop and commercialize Mycovia’s investigational drug, VT-1161 (otesaconazole), in China, including mainland China, Hong Kong, Macau, and Taiwan, for the treatment or prevention of a range of fungal conditions, including recurrent vulvovaginal candidiasis (RVVC), onychomycosis and invasive fungal infections.

Pfizer to buy Array BioPharma for £9.06bn

Pfizer has signed an agreement to acquire commercial stage biopharmaceutical firm, Array BioPharma, for an enterprise value of around $11.4bn (£9.06bn).

IBM, KPMG, Merck and Walmart to assess use of blockchain to protect pharmaceutical product integrity

IBM, KPMG, Merck and Walmart announced that the companies have been selected by the United States Food and Drug Administration (FDA) to be included in a program in support of the US Drug Supply Chain Security Act (DSCSA) that addresses requirements to identify, track and trace prescription medicines and vaccines distributed within the US.

Vernalis, PhoreMost announce drug discovery collaboration for novel oncology target

Ligand Pharmaceuticals and PhoreMost have announced the signing of a research collaboration agreement between Ligand’s subsidiary Vernalis and PhoreMost on an undisclosed novel oncology target.

Dassault Systèmes to buy Medidata Solutions for £4.5bn

Dassault Systèmes has signed an agreement to acquire US-based Medidata Solutions for an enterprise value of $5.8bn (£4.5bn).